DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more


Nutrilib.com
A comprihensive source of nutritional information

Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis. An Extension Trial.

Information source: Novo Nordisk
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Atrophic Vaginitis

Intervention: 25 micrograms 17-Beta Estradiol (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Novo Nordisk

Official(s) and/or principal investigator(s):
Jan Öhrström, MD, Study Director, Affiliation: Novo Nordisk

Summary

This trial was conducted in the United States of America (USA). This trial aimed to evaluate safety and efficacy of 17-beta Estradiol in the treatment of atrophic vaginitis.

Clinical Details

Official title: Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Estrogen Deficiency-Derived Atrophic Vaginitis

Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Primary outcome:

Relief of vaginal symptoms over 12 months of treatment.

Safety: Long-term effect on the endometrium assessed through evaluation of endometrial biopsies. AEs, clinical laboratory data and serum hormone levels.

Secondary outcome: Vaginal health, vaginal cytology and urethral cytology

Eligibility

Minimum age: 45 Years. Maximum age: 80 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Generally healthy

- Postmenopausal

- Hysterectomized or non-hysterectomized

- Moderate or severe vaginal dryness and soreness

- Successful completion of the study VAG/PD/009/USA

Exclusion Criteria:

- Known, suspected, or past history of breast cancer

- Known, suspected, or past history of hormone-dependent tumor

- Genital bleeding of unknown etiology

- Acute thrombophlebitis or thromboembolic disorders or a past history of these

conditions, associated with previous estrogen use

- Subjects who had adverse events during the final visit, or discontinued prematurely,

or were noncompliant in VAG/PD/009/USA

- Exposure to any investigational new drug (other than what was dispensed in

VAG/PD/009/USA) within the previous 30 days

Locations and Contacts

Additional Information

Starting date: January 1995
Last updated: April 23, 2007

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008